An admixture of thiopentone and propofol was evaluated against propofol for laryngeal mask airway (LMA) insertion. Eighty-one ASA 1 and 2 18-to 65-year-old patients, premedicated with 7.5 mg midazolam orally were assigned randomly to receive either propofol 1% or an admixture of thiopentone and propofol (1.25% and 0.5% respectively), both at a dose of 0.25 ml.kg -1 . Satisfactory conditions for insertion were achieved with the admixture, which was comparable to propofol (73% vs 85%, P>0.05). There was no statistical difference in the incidence or severity of gagging, coughing, inadequate jaw relaxation and laryngospasm. The incidence of hypotension was lower in the admixture group (51% vs 78%, P=0.02). The duration of apnoea was not different between the admixture and propofol group (mean 103s vs 109 s respectively, P>0.05) . We conclude that thiopentone/propofol admixture can be a suitable alternative to propofol for LMA insertion, producing less hypotension while allowing cost savings of up to 45%.
Intravenous propofol, with or without opioids, has been the preferred induction agent for laryngeal mask airway (LMA) insertion. It rapidly achieves an adequate depth of anaesthesia and depression of airway reflexes, allowing easier insertion of the LMA with a reduced incidence of side-effects such as coughing, gagging or laryngospasm. However, propofol is expensive and causes hypotension. Moreover, the preparation promotes the growth of microorganisms.
This study aims to investigate whether an admixture of thiopentone and propofol can be a suitable alternative to propofol in relation to ease of insertion of the LMA, haemodynamic stability and cost containment.
METHODS
After approval from our hospital ethics committee, 81 ASA 1 and 2 patients, aged 18 to 65 years, who were undergoing surgery where the use of an LMA was appropriate, consented to participate in this prospective randomized double-blinded trial. Patients who were at risk of regurgitation, those with known allergy to either agents or those with an obviously difficult airway were excluded from the trial. All patients were premedicated with oral midazolam 7.5 mg.
Standard monitoring (ECG, SpO 2 , and NIBP) was applied and the parameters were recorded every minute for the first five minutes. Patients were randomly allocated to receive either 0.25 ml.kg -1 of the admixture (thiopentone 1.25%: propofol 0.5%), or propofol 1% 0.25ml.kg -1 with 10 mg of lignocaine.
The admixture was prepared by drawing equal volumes of 1% propofol and 2.5% thiopentone into a syringe, and was indistinguishable from propofol visually. Strict measures were taken to avoid cross contamination. The propofol was drawn into syringes once the ampoule was broken and mixed with thiopentone. The admixture syringes were stored at operating theatre room temperature (21 to 23°C) and were used within 24 hours. Drug for the propofol group was drawn just prior to induction. The drugs were prepared and given by another anaesthetist. An extra 10ml syringe of the allocated drugs was prepared in case of the need to deepen anaesthesia with additional boluses of the induction agents.
After three minutes of pre-oxygenation, anaesthesia was induced with 1 µg.kg -1 of fentanyl followed by the prepared induction agents, given over 30 seconds through an intravenous cannula. An appropriate size LMA was inserted by an investigator blinded to the drugs 60 seconds later.
The investigator inserting the laryngeal mask dictated the requirement of additional boluses of either induction agent, in 2 ml aliquots, to deepen anaesthesia. Adverse responses to airway manipulation were noted and these include inadequate jaw relaxation, coughing, gagging and laryngospasm. Each adverse response was graded as "mild" if the response was transient and minimal, lasting <5 s, "moderate" if the response lasted >5 s but resolved spontaneously within 20 s and "severe" if the response was sustained beyond 20 s or required further boluses of drugs.
The overall ease of insertion of the LMA was graded as "excellent" when there were no adverse responses, "satisfactory" when there were adverse responses to airway manipulation but not affecting insertion and "poor" when moderate or severe adverse responses occur. Those that required further boluses of drugs or when more than two attempts were required at LMA insertion were also graded as "poor".
Incidence of apnoea, defined as absence of spontaneous respiration clinically of more than 20 s after LMA insertion, and its duration was noted. The occurrence of hypotension, defined as a 20% drop in the systolic blood pressure from baseline, was noted. Hypotension was corrected with fluid loading. After insertion of the LMA, anaesthesia was continued with 30% oxygen in nitrous oxide and 1.5% isoflurane.
Statistics
Parametric data, including demographic data, mean apnoea time and mean rescue doses were analyzed using Student's t-test. The categorical data were analyzed with Chi-square test (incidence of hypotension) and two-tail Mann-Whitney U method (incidence and severity of side-effects and grading of ease of insertion). The sample size was determined by power analysis 80% to detect a 20% difference between the two groups. The 5% level of probability (P<0.05) was taken as significant.
RESULTS
There were 40 patients in the propofol group and 41 patients in the admixture group. The groups were comparable with respect to gender distribution, ASA status, mean weight and age ( Table 1) .
The incidences of gagging, inadequate jaw relaxation and coughing were higher in the admixture but were comparable statistically ( Table 2 ). The severity of gagging, inadequate jaw relaxation and coughing are shown in (Figures 1, 2 and 3 ). None of our patients developed laryngospasm. The requirement of additional boluses of induction agent was comparable in both groups and the mean rescue doses (in ml) were not significantly different ( Table 2) .
All 81 patients in this study had a laryngeal mask successfully inserted. The overall ease of laryngeal mask insertion is as shown in Figure 4 . Of the patients in the admixture group, 73% had satisfactory to excellent conditions for LMA insertion. This is not statistically different from that of propofol group, There were no significant differences in the demographic data between the two groups. where 85% of patients had similar conditions for LMA insertion ( Table 3 ). Incidence of apnoea and its mean duration were comparable between the two groups ( Table 4 ). There was, however, a significantly higher proportion of patients in the propofol group who developed hypotension during the first five minutes after intravenous induction (Table 4 ).
DISCUSSION
Intravenous thiopentone can be used to facilitate LMA insertion. It is less costly, does not cause pain on injection and causes less hypotension when compared to propofol. Thiopentone as a sole agent for LMA insertion is, however, associated with a higher incidence of adverse responses like gagging, coughing and laryngospasm. These, in addition to inadequate jaw relaxation, render insertion impossible at times 1 . Thus, adjunct drugs are frequently added to facilitate smooth and successful insertion. Seavell et al 2 demonstrated the feasibility of using thiopentone with preceding topical lignocaine spray to the posterior pharyngeal wall. It compares favourably to propofol, with the advantage of less apnoea time and better haemodynamic stability. Bapat et al 3 used a co-induction technique of intravenous midazolam three minutes prior to the administration of thiopentone to coincide with the peak effect of both drugs. The insertion conditions were comparable to propofol and a reduction of 35% on cost was quoted.
Naguib and Sari-Kouzel 4 have demonstrated a synergistic interaction between propofol and thiopentone. The recovery characteristics of a combination of propofol and thiopentone were noted to be comparable to propofol 5 . Furthermore, it has been demonstrated that thiopentone pretreatment is more effective or at least comparable to lignocaine in reducing the pain from propofol injection 6, 7 . Thus a thiopentone/propofol admixture is a potentially useful induction regimen.
Thiopentone and propofol are compatible and stable in the admixture as used in our study [8] [9] [10] . Interestingly, Crowther et al 11 demonstrated that the admixture has bactericidal properties and does not support the growth of microorganisms despite the presence of nutrients in the admixture. Chernin and Smiler 12 have reported their clinical experience with the admixture and found it a novel approach to cost containment, while taking advantage of the best features of the two most commonly used agents for induction.
With the use of the thiopentone/propofol admixture in our study, we were able to achieve comparable conditions for LMA insertion as our standard induction regimen using propofol with lignocaine. Although there were higher incidences of gagging, inadequate jaw relaxation and coughing in the admixture group, this did not cause any failure of LMA insertion at one minute after intravenous induction. Furthermore, it carries the simplicity of a single injection.
If the combination of thiopentone and propofol was synergistic, as suggested above 4 , one would expect the admixture group to achieve better insertion conditions. This was not reflected in our study. The discrepancy may be secondary to a relatively small sample size or more importantly, due to the method of administration of the drugs. They administered the two agents sequentially. More recent work by Jones et al 13 using the admixture as in our study demonstrated an additive rather than synergistic effect.
A fall in systolic blood pressure with propofol induction had been consistently reported in the literature. In our study, a drop in 20% of the systolic blood pressure was the threshold for active intervention. Seventy-eight per cent of our patients had hypotension when induced with propofol ( Table 4 ). The attenuation of fall in systolic blood pressure with the admixture is statistically significant. It is likely that the decreased dose of either agent required for induction with the admixture affected the afterload, and the myocardial contractility to a lesser extent. The relative haemodynamic stability of the admixture has also been demonstrated 13 . The lower incidence of hypotension with the admixture is a potential advantage over propofol when haemodynamic stability is desired, although we are aware that an incidence of 50% hypotension may not be considered as achieving satisfactory conditions.
The acquisition costs of the drugs during the study period were $HK58.60 for a 20 ml ampoule of 1% propofol and $HK28.90 for a 2.5g vial of thiopentone, which we reconstituted to 2.5% concentration. The per ml prices of propofol and thiopentone were thus $HK2.93 and $HK0.29 respectively. Using our study regimen, for a 70 kg patient, the calculated cost of induction using propofol was $HK51.28 and $HK28.18 with the admixture. There is a potential saving of 45% on drug cost when drug wastage is kept to a minimum. Note must be taken that the generic form of propofol was not available at our institution during the study period.
In conclusion, thiopentone/propofol admixture can be a suitable alternative to propofol for LMA insertion. In this study, it provided adequate conditions for successful LMA insertion, is cheaper and caused less hypotension. This admixture does not eliminate the problem of hypotension associated with propofol.
